We are pleased to announce that our company has successfully obtained the CEP (Certificate of European Pharmacopoeia) for Esketamine.

Esketamine is a promising drug used for the treatment of treatment-resistant depression. It is a form of ketamine, which has been used as an anesthetic for many years. Esketamine has the potential to offer a new option to people who do not respond sufficiently to conventional antidepressants.

Obtaining the CEP for Esketamine confirms the high quality and conformity of our manufacturing process with the standards of the European Pharmacopoeia. It is a testament to our commitment to stringent quality controls and adherence to strict regulations to ensure that the drug has the required efficacy and safety.